4C Medical Technologies, a Minneapolis, MN-based medical technology company, raised $35M in Series C funding.
The round was led by MicroPort CardioFlow Medtech Corporation (HKEX:2160).
The company intends to use the funds to develop its AltaValve TMVR technology and highlight its differentiated design, as well as to expand the treatable patient population using their streamlined procedures.
Led by newly appointed President & Chief Executive Officer Saravana Kumar, PhD, and Dr. Jeff Chambers, Founder and Chairman of the Board, 4C Medical is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. Subject to regulatory approvals, the company’s AltaValve would be MR treatment with atrial-only fixation that is designed to minimize known issues associated with current TMVR technologies, which use placement and fixation within the native mitral annulus.
FinSMEs
01/04/2022